[Skip to Content]
Dermatology

Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab

JAMA Oncology
July 25, 2019 Audio Interview 19 min 25 sec
<title>Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab</title>
Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab
Download MP3

Interview with Suzanne L. Topalian, MD, author of Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
Read Transcript

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Related

  1. Five-Year Survival Among Patients With Advanced Skin, Renal, and Lung Cancer Treated With Nivolumab
    1.00 CME

See More About

Nephrology Oncology Targeted and Immune Cancer Therapy Dermatology Melanoma Skin Cancer Urologic Cancer Urology Lung Cancer

Name Your Search

Save Search
Privacy Policy|Terms of Use

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Topics
State Requirements
Privacy Policy | Terms of Use
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue